PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
A Glaviano, ASC Foo, HY Lam, KCH Yap, W Jacot… - Molecular cancer, 2023 - Springer
Abstract The PI3K/AKT/mTOR (PAM) signaling pathway is a highly conserved signal
transduction network in eukaryotic cells that promotes cell survival, cell growth, and cell …
transduction network in eukaryotic cells that promotes cell survival, cell growth, and cell …
Cancer-associated venous thromboembolism
AA Khorana, N Mackman, A Falanga… - Nature reviews Disease …, 2022 - nature.com
Cancer-associated thrombosis (including venous thromboembolism (VTE) and arterial
events) is highly consequential for patients with cancer and is associated with worsened …
events) is highly consequential for patients with cancer and is associated with worsened …
Complex heatmap visualization
Z Gu - Imeta, 2022 - Wiley Online Library
Heatmap is a widely used statistical visualization method on matrix‐like data to reveal
similar patterns shared by subsets of rows and columns. In the R programming language …
similar patterns shared by subsets of rows and columns. In the R programming language …
Emerging therapies for glioblastoma: current state and future directions
L Rong, N Li, Z Zhang - Journal of Experimental & Clinical Cancer …, 2022 - Springer
Glioblastoma (GBM) is the most common high-grade primary malignant brain tumor with an
extremely poor prognosis. Given the poor survival with currently approved treatments for …
extremely poor prognosis. Given the poor survival with currently approved treatments for …
Federated learning enables big data for rare cancer boundary detection
Although machine learning (ML) has shown promise across disciplines, out-of-sample
generalizability is concerning. This is currently addressed by sharing multi-site data, but …
generalizability is concerning. This is currently addressed by sharing multi-site data, but …
Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target
A major rate-limiting step in developing more effective immunotherapies for GBM is our
inadequate understanding of the cellular complexity and the molecular heterogeneity of …
inadequate understanding of the cellular complexity and the molecular heterogeneity of …
Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial
PY Wen, A Stein, M van den Bent, J De Greve… - The lancet …, 2022 - thelancet.com
Background Effective treatments are needed to improve outcomes for high-grade glioma
and low-grade glioma. The activity and safety of dabrafenib plus trametinib were evaluated …
and low-grade glioma. The activity and safety of dabrafenib plus trametinib were evaluated …
Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial
IK Mellinghoff, M Lu, PY Wen, JW Taylor, EA Maher… - Nature medicine, 2023 - nature.com
Vorasidenib and ivosidenib inhibit mutant forms of isocitrate dehydrogenase (mIDH) and
have shown preliminary clinical activity against m IDH glioma. We evaluated both agents in …
have shown preliminary clinical activity against m IDH glioma. We evaluated both agents in …
Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance
Glioblastoma multiforme (GBM) is a WHO grade IV glioma and the most common malignant,
primary brain tumor with a 5-year survival of 7.2%. Its highly infiltrative nature, genetic …
primary brain tumor with a 5-year survival of 7.2%. Its highly infiltrative nature, genetic …
Glioma progression is shaped by genetic evolution and microenvironment interactions
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify
treatment-associated cellular and genetic changes, we analyzed RNA and/or DNA …
treatment-associated cellular and genetic changes, we analyzed RNA and/or DNA …